Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

CAR-T for Chronic Lymphocytic Leukemia Receives FDA Approval.

2.

Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients

3.

PSA Screening May Modestly Curb Prostate Cancer Deaths

4.

Extended lymphadenectomy has no survival benefit in patients with muscle-invasive bladder cancer.

5.

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot